BerGenBio ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.
Market Cap & Net Worth: BerGenBio ASA (BRRGF)
BerGenBio ASA (PINK:BRRGF) has a market capitalization of $611.08 Million ($611.08 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #16543 globally and #6360 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BerGenBio ASA's stock price $2.50 by its total outstanding shares 244433358 (244.43 Million).
BerGenBio ASA Market Cap History: 2018 to 2025
BerGenBio ASA's market capitalization history from 2018 to 2025. Data shows change from $996.80 Million to $611.08 Million (-6.57% CAGR).
BerGenBio ASA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BerGenBio ASA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
720.62x
BerGenBio ASA's market cap is 720.62 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $996.80 Million | $2.33 Million | -$191.75 Million | 426.89x | N/A |
| 2019 | $391.09 Million | $8.90 Million | -$199.39 Million | 43.94x | N/A |
| 2020 | $963.07 Million | $601.00K | -$257.06 Million | 1602.44x | N/A |
| 2021 | $515.75 Million | $774.00K | -$309.42 Million | 666.35x | N/A |
| 2022 | $432.65 Million | $389.00K | -$298.61 Million | 1112.20x | N/A |
| 2023 | $6.11 Million | $354.00K | -$190.40 Million | 17.26x | N/A |
| 2024 | $611.08 Million | $848.00K | -$139.28 Million | 720.62x | N/A |
Competitor Companies of BRRGF by Market Capitalization
Companies near BerGenBio ASA in the global market cap rankings as of March 19, 2026.
Key companies related to BerGenBio ASA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
BerGenBio ASA Historical Marketcap From 2018 to 2025
Between 2018 and today, BerGenBio ASA's market cap moved from $996.80 Million to $ 611.08 Million, with a yearly change of -6.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $611.08 Million | 0.00% |
| 2024 | $611.08 Million | +9900.00% |
| 2023 | $6.11 Million | -98.59% |
| 2022 | $432.65 Million | -16.11% |
| 2021 | $515.75 Million | -46.45% |
| 2020 | $963.07 Million | +146.25% |
| 2019 | $391.09 Million | -60.77% |
| 2018 | $996.80 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of BerGenBio ASA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $611.08 Million USD |
| MoneyControl | $611.08 Million USD |
| MarketWatch | $611.08 Million USD |
| marketcap.company | $611.08 Million USD |
| Reuters | $611.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.